Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 351

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation

Open access
Nijenhuis, Vincent J., Brouwer, Jorn, Delewi, Ronak, Hermanides, Renicus S., Holvoet, Wouter, Dubois, Christophe L.F., Frambach, Peter, De Bruyne, Bernard, van Houwelingen, Gert K., Van Der Heyden, Jan A.S., Toušek, Petr, van der Kley, Frank, Buysschaert, Ian, Schotborgh, Carl E., Ferdinande, Bert, van der Harst, Pim, Roosen, John, Peper, Joyce, Thielen, Frederick W.F., Veenstra, Leo, Chan Pin Yin, Dean R.P.P., Swaans, Martin J., Rensing, Benno J.W.M., van ’t Hof, Arnoud W.J., Timmers, Leo, Kelder, Johannes C., Stella, Pieter R., Baan, Jan, ten Berg, Jurriën M.·2020·New England Journal of Medicine

Abstract

BACKGROUND: The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied. METHODS: We performed a randomized trial of clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation for appropriate indications. Patients were assigned before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel for 3 months. The two primary outcomes were all bleeding and non-procedure-related bleeding over a period of 12 months. Procedure-related bleeding was defined as Bleeding Academic Research Consortium type 4 severe bleeding, and therefore most bleeding at the puncture site was counted as non-procedure-related. The two secondary outcomes were a composite of death from cardiovascular causes, non-procedure-related bleeding, stroke, or myocardial infarction at 12 months (secondary composite 1) and a composite of death from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary composite 2), both tested for noninferiority (noninferiority margin, 7.5 percentage points) and superiority. RESULTS: Bleeding occurred in 34 of the 157 patients (21.7%) receiving oral anticoagulation alone and in 54 of the 156 (34.6%) receiving oral anticoagulation plus clopidogrel (risk ratio, 0.63; 95% confidence interval [CI], 0.43 to 0.90; P = 0.01); most bleeding events were at the TAVI access site. Non-procedure-related bleeding occurred in 34 patients (21.7%) and in 53 (34.0%), respectively (risk ratio, 0.64; 95% CI, 0.44 to 0.92; P = 0.02). Most bleeding occurred in the first month and was minor. A secondary composite 1 event occurred in 49 patients (31.2%) receiving oral anticoagulation alone and in 71 (45.5%) receiving oral anticoagulation plus clopidogrel (difference, -14.3 percentage points; 95% CI for noninferiority, -25.0 to -3.6; risk ratio, 0.69; 95% CI for superiority, 0.51 to 0.92). A secondary composite 2 event occurred in 21 patients (13.4%) and in 27 (17.3%), respectively (difference, -3.9 percentage points; 95% CI for noninferiority, -11.9 to 4.0; risk ratio, 0.77; 95% CI for superiority, 0.46 to 1.31). CONCLUSIONS: In patients undergoing TAVI who were receiving oral anticoagulation, the incidence of serious bleeding over a period of 1 month or 1 year was lower with oral anticoagulation alone than with oral anticoagulation plus clopidogrel. (Funded by the Netherlands Organization for Health Research and Development; POPular TAVI EU Clinical Trials Register number, 2013-003125-28; ClinicalTrials.gov number, NCT02247128.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1915152

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 351

Metadata

Authors
Nijenhuis, V. J., Brouwer, J., Delewi, R., Hermanides, R. S., Holvoet, W., Dubois, C. L. F., Frambach, P., De Bruyne, B., van Houwelingen, G. K., Van Der Heyden, J. A. S., Toušek, P., van der Kley, F., Buysschaert, I., Schotborgh, C. E., Ferdinande, B., van der Harst, P., Roosen, J., Peper, J., Thielen, F. W. F., Veenstra, L., Chan Pin Yin, D. R. P. P., Swaans, M. J., Rensing, B. J. W. M., van ’t Hof, A. W. J., Timmers, L., Kelder, J. C., Stella, P. R., Baan, J., & ten Berg, J. M.
Venue
New England Journal of Medicine
Published
2020-04-30
Volume
382
Issue
18
Pages
1696-1707
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3013514162
Cited by
351
References
26
FWCI
34.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. https://app.cochat.ai/papers/10.1056/nejmoa1915152
The paper
Nijenhuis, V. J., Brouwer, J., Delewi, R., Hermanides, R. S., Holvoet, W., Dubois, C. L. F., Frambach, P., De Bruyne, B., van Houwelingen, G. K., Van Der Heyden, J. A. S., Toušek, P., van der Kley, F., Buysschaert, I., Schotborgh, C. E., Ferdinande, B., van der Harst, P., Roosen, J., Peper, J., Thielen, F. W. F., . . . ten Berg, J. M. (2020). Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1915152

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.